What are the functions and efficacy of erdafitinib?

Erdafitinib, a revolutionary oral anti-cancer drug, occupies an important position in the field of modern tumor treatment due to its mechanism of action and therapeutic effect. Erdafitinib is mainly used to treat a variety of malignant tumors, such as lung cancer, colorectal cancer, gastric cancer, etc., but it is particularly worth mentioning that it has shown good results in the treatment of locally advanced or metastatic urothelial cancer. For patients with FGFR2 or FGFR3 gene alterations, erdafitinib effectively prevents the proliferation and spread of tumor cells by inhibiting the activity of these abnormal genes.

Secondly, from the perspective of its mechanism of action, erdafitinib is a tyrosine kinase inhibitor that can accurately bind to the fibroblast growth factor receptor (FGFR) and block the signal transduction process triggered by fibroblast growth factor. This mechanism allows erdafitinib to accurately attack tumor cells while reducing damage to normal cells.

In clinical studies, erdafitinib has demonstrated good efficacy. For example, in a clinical trial of patients with urothelial cancer, patients treated with erdafitinib had a 36% lower risk of death and a longer median survival. These data fully demonstrate the effectiveness of erdafitinib in the treatment of malignant tumors.

In addition, erdafitinib has also demonstrated good tolerability and oral convenience, making it easier for patients to receive treatment. However, as an anti-cancer drug, erdafitinib also has certain side effects, such as nausea, vomiting, diarrhea, etc., but usually these symptoms can be alleviated through appropriate drug adjustments or supportive treatment.

In summary, erdafitinib, with its mechanism of action and therapeutic effect, provides a new treatment option for patients with malignant tumors, especially in the treatment of specific types of cancer such as urothelial carcinoma, showing great potential and value.